Our mission begins with the word cure. We aim to lead the way to cures for blood cancers through groundbreaking research. For more than 70 years, our support has been pivotal in the development of nearly every breakthrough in blood cancer treatment.
The Translational Research Program (TRP) grants are dedicated to funding innovative research that exhibits a high promise for moving from laboratory discoveries to clinical application, specifically aiming to accelerate the journey from laboratory findings to actual treatments for blood cancers. The program emphasizes the importance of reducing the time between laboratory findings and treatment implementation, fostering research that is directly translatable to better treatments and cures for blood cancers. The focus is on applications proposing novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related conditions. Areas of interest include novel immunotherapy approaches, the interaction between cancer cells and their microenvironment, personalized medicine, the safety and efficacy of stem cell transplantation, long-term outcome assessment following therapies, and treatment of immunocompromised blood cancer patients, particularly in the context of infectious diseases like COVID-19. The program also highlights opportunities for co-funding with other foundations for researchers in Australia and Canada.